1. Manikandan, P. & Nagini, S. Cytochrome P450 Structure, Function and Clinical Significance: A Review. Curr Drug Targets 19, 38-54, doi:10.2174/1389450118666170125144557 (2018).
2. Ma, C. X., Reinert, T., Chmielewska, I. & Ellis, M. J. Mechanisms of aromatase inhibitor resistance. Nature Reviews Cancer 15, 261-275, doi:10.1038/nrc3920 (2015).
3. Guengerich, F. P. A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. Toxicol Res, 1-23, doi:10.1007/s43188-020-00056-z (2020).
4. Munkboel, C. H. et al. The classic azole antifungal drugs are highly potent endocrine disruptors in vitro inhibiting steroidogenic CYP enzymes at concentrations lower than therapeutic Cmax. Toxicology 425, 152247, doi:10.1016/j.tox.2019.152247 (2019).
5. Adis Medical, W. Long-term use of systemic azole antifungals can result in hepatotoxicity and other serious adverse effects. Drugs & Therapy Perspectives 36, 112-115, doi:10.1007/s40267-019-00699-5 (2020).
6. Kitts, A., Phan, L., Ward, M. & Holmes, J. B. in The NCBI Handbook [Internet]. 2nd edition (National Center for Biotechnology Information (US), 2014).
7. Foroozesh, M., Sridhar, J., Goyal, N. & Liu, J. Coumarins and P450s, Studies Reported to-Date. Molecules 24, doi:10.3390/molecules24081620 (2019).
8. No organic photocages were found for CYP inhibitors in a search of the literature.
9. Zamora, A. et al. Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage. Dalton Trans 46, 2165 - 2173, doi:10.1039/c6dt04405k (2017).
10. Li, A. et al. Illuminating cytochrome P450 binding: Ru(II)-caged inhibitors of CYP17A1. Chem. Commun. 53, 3673-3676, doi:10.1039/c7cc01459g (2017).
11. Toupin, N. et al. Photosensitive Ru(II) Complexes as Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4. J Am Chem Soc 143, 9191-9205, doi:10.1021/jacs.1c04155 (2021).
12. Golbaghi, G. et al. Organoruthenium(II) Complexes Bearing an Aromatase Inhibitor: Synthesis, Characterization, in Vitro Biological Activity and in Vivo Toxicity in Zebrafish Embryos. Organometallics 38, 702-711, doi:10.1021/acs.organomet.8b00897 (2019).
13. Rubbiani, R. et al. In vivo Active Organometallic-containing Antimycotic Agents. RSC Chemical Biology, doi:10.1039/D1CB00123J (2021).
14. Area values calculated for Ru(tpy)(6,6'dmbpy) and for Ru(typ)(bca).
15. Dunn, A. R., Dmochowski, I. J., Bilwes, A. M., Gray, H. B. & Crane, B. R. Probing the open state of cytochrome P450cam with ruthenium-linker substrates. Proc Natl Acad Sci U S A 98, 12420-12425, doi:10.1073/pnas.221297998221297998 [pii] (2001).
16. Dunn, A. R. et al. Fluorescent probes for cytochrome p450 structural characterization and inhibitor screening. J Am Chem Soc 124, 10254-10255, doi:ja0271678 [pii] (2002).
17. Hays, A. M. et al. Conformational states of cytochrome P450cam revealed by trapping of synthetic molecular wires. J. Mol. Biol. 344, 455-469, doi:10.1016/j.jmb.2004.09.046 (2004).
18. Glazer, E. C., Lee, Y. T., Wilson, R. F., Stout, C. D. & Goodin, D. B. Three clusters of conformational states in p450cam reveal a multistep pathway for closing of the substrate access channel. Biochemistry 50, 693-703, doi:10.1021/bi101726d (2011).
19. Carrera, Alexa N., Grant, Marianne K. O. & Zordoky, Beshay N. CYP1B1 as a therapeutic target in cardio-oncology. Clinical Science 134, 2897-2927, doi:10.1042/CS20200310 %J Clinical Science (2020).
20. Horley, N. J. et al. Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines. Eur. J. Med. Chem. 129, 159-174, doi:10.1016/j.ejmech.2017.02.016 (2017).
21. Huang, R. S. et al. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res 68, 3161-3168, doi:10.1158/0008-5472.CAN-07-6381 (2008).
22. Chang, I. et al. Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma. Oncotarget 6, 7774-7787, doi:10.18632/oncotarget.3484 (2015).
23. De Iuliis, F., Salerno, G., Taglieri, L. & Scarpa, S. Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review. Cancer Chemother Pharmacol 76, 679-690, doi:10.1007/s00280-015-2818-4 (2015).
24. Dumont, A. et al. ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors. Springerplus 4, 327, doi:10.1186/s40064-015-1053-0 (2015).
25. Sissung, T. M. et al. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther 7, 19-26, doi:10.1158/1535-7163.MCT-07-0557 (2008).
26. So-called Type II coordinating inhibitors are used in the clinic for CYP19A1 (anastrozole and letrozole), 17A1, CYP11B1 (metyrapone), and fungal CYP51 (including ketoconazole, fluconazole, itraconazole, and many others).
27. Havrylyuk, D., Deshpande, M., Parkin, S. & Glazer, E. C. Ru(II) complexes with diazine ligands: electronic modulation of the coordinating group is key to the design of "dual action" photoactivated agents. Chem. Commun. 54, 12487-12490, doi:10.1039/c8cc05809a (2018).
28. Wang, A., Savas, U., Stout, C. D. & Johnson, E. F. Structural characterization of the complex between alpha-naphthoflavone and human cytochrome P450 1B1. J Biol Chem 286, 5736-5743, doi:10.1074/jbc.M110.204420 (2011).
29. Heidary, D. K., Kriger, S. M., Hachey, A. C. & Glazer, E. C. A Fluorometric CYP19A1 (Aromatase) Activity Assay in Live Cells. ChemMedChem, doi:10.1002/cmdc.202100326 (2021).
30. Zhang, H. et al. Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo. Scientific Reports 5, 17671, doi:10.1038/srep17671 (2015).
31. Commercial preparations come from 50 individuals.
32. Grimm, S. W. & Dyroff, M. C. Inhibition of Human Drug Metabolizing Cytochromes P450 by Anastrozole, a Potent and Selective Inhibitor of Aromatase. Drug Metabolism and Disposition 25, 598-602 (1997).
33. Hoobler, E. K. et al. Discovery of a novel dual fungal CYP51/human 5-lipoxygenase inhibitor: implications for anti-fungal therapy. PLoS One 8, e65928, doi:10.1371/journal.pone.0065928 (2013).
34. The reported IC50 is 40 nM. Two molecules of keotconozole are found in the crystal structure, and binding appears to be cooperative.
35. Sevrioukova, I. F. & Poulos, T. L. Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems. Dalton Transactions 42, 3116-3126, doi:10.1039/C2DT31833D (2013).
36. This hypothesis is related to the prevalence of the 1,2,4-triazole ring in CYP inhibitors, in contrast to the less basic 1,2,3-triazole ring. See K. P. Conner, P. Vennam, C. M. Woods, M. D. Krzyaniak, M. K. Bowman, W. M. Atkins, Biochemistry 2012, 51, 6441-6457.
37. Havrylyuk, D., Stevens, K., Parkin, S. & Glazer, E. C. Toward Optimal Ru(II) Photocages: Balancing Photochemistry, Stability, and Biocompatibility Through Fine Tuning of Steric, Electronic, and Physiochemical Features. Inorg. Chem. 59, 1006-1013, doi:10.1021/acs.inorgchem.9b02065 (2020).
38. Wachter, E., Heidary, D. K., Howerton, B. S., Parkin, S. & Glazer, E. C. Light-activated ruthenium complexes photobind DNA and are cytotoxic in the photodynamic therapy window. ChemComm 48, 9649-9651, doi:10.1039/c2cc33359g (2012).
39. Görner, H. & Kuhn, H. J. in Advances in Photochemistry 1-117 (1994).
40. Respondek, T. et al. Light activation of a cysteine protease inhibitor: caging of a peptidomimetic nitrile with Ru(II)(bpy)2. J. Am. Chem. Soc. 133, 17164-17167, doi:10.1021/ja208084s (2011).
41. Zayat, L., Calero, C., Albores, P., Baraldo, L. & Etchenique, R. A new strategy for neurochemical photodelivery: metal-ligand heterolytic cleavage. J. Am. Chem. Soc. 125, 882-883, doi:10.1021/ja0278943 (2003).
42. Zayat, L., Salierno, M. & Etchenique, R. Ruthenium(II) bipyridyl complexes as photolabile caging groups for amines. Inorg. Chem. 45, 1728-1731, doi:10.1021/ic0512983 (2006).
43. Bonnet, S., Collin, J.-P., Sauvage, J.-P. & Schofield, E. Photochemical Expulsion of the Neutral Monodentate Ligand L in Ru(Terpy*)(Diimine)(L)2+: A Dramatic Effect of the Steric Properties of the Spectator Diimine Ligand. Inorg. Chem. 43, 8346-8354, doi:10.1021/ic0491736 (2004).
44. Donthamsetti, P. et al. Selective Photoswitchable Allosteric Agonist of a G Protein-Coupled Receptor. J. Am. Chem. Soc. 143, 8951-8956, doi:10.1021/jacs.1c02586 (2021).
45. Kolarski, D. et al. Photopharmacological Manipulation of Mammalian CRY1 for Regulation of the Circadian Clock. J. Am. Chem. Soc. 143, 2078-2087, doi:10.1021/jacs.0c12280 (2021).
46. Zayat, L., Filevich, O., Baraldo, L. M. & Etchenique, R. Ruthenium polypyridyl phototriggers: from beginnings to perspectives. Philos Trans A Math Phys Eng Sci 371, 20120330, doi:rsta.2012.0330 [pii]10.1098/rsta.2012.0330 (2013).
47. Pérez, Y. R. & Etchenique, R. Optical manipulation of animal behavior using a ruthenium-based phototrigger. Photochemical & Photobiological Sciences 18, 208-212, doi:10.1039/c8pp00467f (2019).
48. Huisman, M. et al. Caging the uncageable: using metal complex release for photochemical control over irreversible inhibition. Chem Commun (Camb) 52, 12590-12593, doi:10.1039/c6cc07083c (2016).
49. Arora, K. et al. Catch and Release Photosensitizers: Combining Dual-Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers. J Am Chem Soc 140, 14367-14380, doi:10.1021/jacs.8b08853 (2018).
50. Lameijer, L. N. et al. A Red-Light-Activated Ruthenium-Caged NAMPT Inhibitor Remains Phototoxic in Hypoxic Cancer Cells. Angew. Chem. Int. Ed. Engl. 56, 11549-11553, doi:10.1002/anie.201703890 (2017).
51. van Rixel, V. H. S. et al. Photo-Uncaging of a Microtubule-Targeted Rigidin Analogue in Hypoxic Cancer Cells and in a Xenograft Mouse Model. J Am Chem Soc 141, 18444-18454, doi:10.1021/jacs.9b07225 (2019).
52. Shimada, T. et al. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem Res Toxicol 11, 1048-1056, doi:10.1021/tx980090+ (1998).
53. Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27, 221-234, doi:10.1007/s10822-013-9644-8 (2013).
54. Jacobson, M. P., Friesner, R. A., Xiang, Z. & Honig, B. On the Role of the Crystal Environment in Determining Protein Side-chain Conformations. Journal of Molecular Biology 320, 597-608, doi:10.1016/s0022-2836(02)00470-9 (2002).
55. Jacobson, M. P. et al. A hierarchical approach to all-atom protein loop prediction. Proteins 55, 351-367, doi:10.1002/prot.10613 (2004).
56. Friesner, R. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47, 1739-1749, doi:10.1021/jm0306430 (2004).
57. Halgren, T. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47, 1750-1759, doi:10.1021/jm030644s (2004).
58. Friesner, R. A. et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49, 6177-6196, doi:10.1021/jm051256o (2006).
59. Burke, M. D. & Mayer, R. T. Ethoxyresorufin: direct fluorimetric assay of a microsomal O-dealkylation which is preferentially inducible by 3-methylcholanthrene. Drug Metab Dispos 2, 583-588 (1974).